AN2 Therapeutics Reports $8.2 Million Net Loss in Q2 2026, Increases R&D Spending

AN2 Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $8.2 million, compared to a net loss of $6.5 million for the same period in 2025. For the six months ended June 30, 2026, the company incurred a net loss of $18.2 million, slightly higher than the $17.1 million loss recorded in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $6.0 million in the second quarter, an 88% increase from $3.2 million in the same quarter of 2025. General and administrative expenses decreased by 28% to $2.9 million, down from $4.0 million in the previous year.

The company’s total operating expenses for the second quarter of 2026 were $8.9 million, a 23% increase from $7.2 million in the prior year. The rise in operating expenses was primarily driven by increased costs associated with chemistry manufacturing and controls, consulting services, and clinical trial activities. In contrast, personnel-related expenses saw a decrease, reflecting a reduction in stock-based compensation. The company reported interest income of $0.7 million for the quarter, a slight decline from $0.8 million in the previous year.

AN2 Therapeutics has made significant strides in its operational strategy, including the expansion of its clinical pipeline. The company is advancing its lead product candidate, epetraborole, into a Phase 2 proof-of-concept study for phlebotomy-dependent polycythemia vera, with enrollment expected to begin in late 2026. Additionally, the company is supporting an investigator-initiated trial for epetraborole in M. abscessus lung disease, with topline results anticipated in late 2027. The company also announced an exclusive license agreement with the University of Georgia Research Foundation to further develop AN2-502998 for chronic Chagas disease.

As of June 30, 2026, AN2 Therapeutics reported cash, cash equivalents, and investments totaling $79.9 million, a significant increase from $61.9 million at the end of 2025. This increase was bolstered by net proceeds of $37.2 million from a private placement and $1.4 million from at-the-market offerings. The company believes its current cash reserves will be sufficient to fund operations for at least the next twelve months. However, it anticipates needing substantial additional capital to support ongoing research and development activities, as it has not yet generated revenue from product sales and continues to incur significant operating losses.

Looking ahead, AN2 Therapeutics remains focused on advancing its clinical programs while managing its financial resources prudently. The company acknowledges the inherent risks and uncertainties in drug development and the need for additional funding to achieve its strategic objectives. Future capital requirements will depend on various factors, including the progress of clinical trials, regulatory approvals, and the overall market conditions affecting the biopharmaceutical industry.